An Open-Label Extension Study to Assess the Long-term Safety and Tolerability of ATN-103 in Subjects With Rheumatoid Arthritis.
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2016
At a glance
- Drugs Ozoralizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 09 Nov 2012 Results will be presented at the 2012 American College of Rheumatology Annual Meeting according to an Ablynx media release.
- 25 Jun 2012 Results released by Ablynx.
- 26 Mar 2012 Actual patient number is 266 according to ClinicalTrials.gov.